

**IX BIOPHARMA LTD**  
(Incorporated in Singapore)  
(Company Registration No. 200405621W)

---

**ISSUE AND ALLOTMENT OF SHARES PURSUANT TO EXERCISE OF WARRANTS**

---

The Board of Directors (the “**Board**”) of iX Biopharma Ltd. (the “**Company**”), and together with its subsidiaries, the “**Group**”) wishes to announce that on 6 May 2026, the Company has allotted and issued 143,572 new ordinary shares pursuant to the exercise of warrants at the exercise price of S\$0.06 per warrant share, following which the number of issued shares of the Company has increased from 1,050,752,024 shares to 1,050,895,596 shares.

The new ordinary shares rank *pari passu* in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 8 May 2026. Pursuant to the aforesaid exercise of warrants, a cumulative total of 20,136,151 warrants, representing 35.01% of all warrants previously issued, have now been exercised and there are 37,373,328 outstanding warrants with an exercise price of S\$0.06 for each warrant share expiring on 18 July 2026.

Warrant holders may refer to <https://www.ixbiopharma.com/warrants/> for instruction on how to exercise their warrants.

**BY ORDER OF THE BOARD**

Eddy Lee Yip Hang  
Chairman & CEO  
6 May 2026

---

*This announcement has been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.*